Smith Group Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Smith Group Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-76,410	Closed	-$789K	–	466
2015 Q4	$789K	Buy	+76,410	New	+$760K	0.02%	185
2014 Q1	–	Sell	-291,983	Closed	-$2.22M	–	408
2013 Q4	$2.22M	Sell	291,983 -1,613	-0.5%	-$10.2K	0.08%	156
2013 Q3	$2.14M	Sell	293,596 -8,600	-3%	-$43.6K	0.09%	155
2013 Q2	$468K	Buy	+302,196	New	+$521K	0.02%	209

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Smith Group Asset Management's BCRX Position: Q1 2016 in Review

Smith Group Asset Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2016, closing a stake of 76,410 shares — an estimated $789K sold.

Smith Group Asset Management first reported a position in BCRX in Q2 2013 and held it in 4 quarters. The position peaked at $2.22M in Q4 2013. 109 funds tracked by Wall St. Rank hold BCRX as of Q1 2016.

Smith Group Asset Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Smith Group Asset Management sold 76,410 BioCryst Pharmaceuticals shares in Q1 2016, an estimated $789K.
Smith Group Asset Management first reported a position in BioCryst Pharmaceuticals in Q2 2013 and held it in 4 quarters.
Smith Group Asset Management's BioCryst Pharmaceuticals position peaked at $2.22M in Q4 2013.
109 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2016.

Based on Smith Group Asset Management's 13F filing for Q1 2016, filed 3 May 2016.